DRMA

Dermata Therapeutics, Inc. (DRMA) Risks & Opportunities Analysis (2026)

Invetso Score: 6.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 6.1 (Moderate)

Dermatology demand remains exposed to payer scrutiny and elective-procedure sensitivity versus larger peers with broader portfolios, limiting pricing and volume resilience.

Smaller commercial scale can leave DRMA more vulnerable to launch timing and reimbursement variability than diversified dermatology peers, pressuring near-term growth visibility.

Net debt to EBITDA of 0.52x suggests manageable leverage, but limited disclosed interest coverage reduces cushion versus cash-rich peers if operating conditions soften.

Opportunities

Score:

A current ratio of 2.81x and quick ratio of 2.73x indicate strong liquidity versus many small-cap peers, supporting commercial execution and working-capital flexibility.

Low leverage versus EBITDA provides balance-sheet headroom relative to more indebted peers, improving capacity to fund launches or absorb reimbursement volatility.

If DRMA sustains access to dermatology channels, focused exposure can outgrow broader peers when category demand and prescribing trends remain favorable.

Overall Score

Score:

DRMA’s forward positioning is supported by solid liquidity and modest leverage, but peer-relative exposure to reimbursement and commercialization volatility keeps the overall profile moderate.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Dermata Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →